Which radiation schedule tames spreading cancer best? new study aims to find out
NCT ID NCT01223248
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two ways of giving high-dose radiation to people whose cancer has spread to bones, spine, soft tissue, or lymph nodes. One schedule gives the radiation in one day, the other over three days. The goal is to see which schedule better controls tumor growth and has fewer side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
220 people
The number who actually took part.
- Started
-
Oct 2010
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of cancer (including epithelial carcinoma, sarcoma, and melanoma) The diagnosis can be done at MSKCC or at participating institutions. * Sites of metastatic disease to be treated on protocol are limited to bone, spine, soft tissue, and lymph nodes only. * Patients with American Joint Committee on Cancer (6th edition, 2002) Stage IV cancer with distant metastases * Age 18 years or older * Life expectancy \>3 months * Maximum tumor dimension of ≤6 cm in lymph nodes, soft tissue, osseous metastases, or spinal metastases seen on imaging (computed tomography \[CT\], magnetic resonance imaging \[MRI\], or PET/CT) and considered amenable for RT. * If the lesion(s) to be treated are soft-tissue or lymph Nodes unidimensionally measurable disease is required. Bone \& spine lesions are eligible even if considered non-measurable. * Measurable disease is defined as: * ≥ 10mm for soft-tissue lesions * ≥ 15mm on the short axis of lymph nodes * KPS ≥ 80 * Patients must have normal bone marrow function as defined below:(within 2 months of registration) Hemoglobin ≥9.0 g/dl Absolute neutrophil count (ANC) ≥1,500/μl Platelets ≥100,000/μl Exclusion Criteria: * Prior radiotherapy delivered to the target region * Disease to be treated on protocol is less than 2 mm from the spinal cord and therefore will not meet dose constraints\* * Pregnancy or Breast-Feeding (Participants of child-bearing potential are eligible but must consent to using effective contraception during therapy and for at least 3 months after completing therapy). * Chemotherapy given on the day of the planned radiotherapy treatment * Lesions which comprise \>70% of the width of weight bearing bones, such as the femur. * Existing cortical bone destruction, where orthopedic stabilization would be required. * Areas to be treated on protocol do not include metastases to liver, brain or lung. * Note: Patients with eligible and ineligible lesions will be accrued to this protocol. Only target eligible lesions will be treated per protocol. Other eligible and ineligible lesions will be treated at the discretion of the treating physician."
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
The Champalimaud Centre
Lisbon, Portugal
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Pisa
Pisa, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Can a Patient's own immune cells fight ovarian cancer?
- Ovarian Cancer's spread: scientists probe abdominal fluid for clues
- New PET tracer aims to light up hidden cancer targets
- New antibody GNR-051 tested for safety in Hard-to-Treat cancers
- Can a Blood-Flow-Blocking drug stall a rare sarcoma?